Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
[Plasmapheresis in central nervous system disorders].
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Generic Midamor
A practical review of the neuropathology and neuroimaging of multiple sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Ono to enter license agreements with Merck KGaA
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.

Pages